TY - JOUR
T1 - Circulating levels of IGF-1, IGFBP-3, and IGF-1/IGFBP-3 molar ratio and colorectal adenomas
T2 - A meta-analysis
AU - Yoon, Yeong Sook
AU - Keum, Na Na
AU - Zhang, Xuehong
AU - Cho, Eunyoung
AU - Giovannucci, Edward L.
N1 - Publisher Copyright:
© 2015.
PY - 2015/12/1
Y1 - 2015/12/1
N2 - Backgrounds: Insulin-like growth factor-1(IGF-1) promotes cell proliferation and inhibits apoptosis, and is thereby implicated in carcinogenesis. Insulin-like growth factor binding protein-3 (IGFBP-3) may antagonize IGF-1 action, leading to inhibition of the potential tumorigenicity of IGF-1. We conducted this meta-analysis to estimate the association between IGF-1, IGFBP-3 and IGF-1/IGFBP-3 ratio and the risk of colorectal adenomas (CRAs). Further, we investigated whether this association was different between occurrent and recurrent CRA, by adjustment for obesity, and by advanced CRA. Materials and methods: Pubmed and Embase were searched up to April, 2015 to identify relevant observational studies and summary odds ratio (OR) and the corresponding 95% confidence interval (95% CI) was estimated using a random-effects model. Results: A total of 12 studies (11 studies including 3038 cases for IGF-1, 12 studies including 3208 cases for IGFBP-3, and 7 studies including 1867 cases for IGF-1/IGFBP-3 ratio) were included in this meta-analysis. The summary ORs of occurrent CRA for the highest versus lowest category of IGF-1, IGFBP-3 and IGF-1/IGFBP-3 ratio were 1.13 (95% CI: 0.95-1.34), 0.99 (0.84-1.16), and 1.05 (0.86-1.29), respectively. Higher IGF-1 and IGF-1/IGFBP-3 ratio were significantly associated with decreased risk of recurrent CRA (OR for IGF-1 = 0.60 [95% CI: 0.42-0.85]; IGF-1/IGFBP-3 ratio = 0.65 [0.44-0.96]). A stratified analysis by advancement of occurrent CRA produced a significant summary OR of IGF-1 for advanced CRA (OR = 2.21 [1.08-4.52]) but not for non-advanced CRA (OR = 0.89 [0.55-1.45]). We did not find significant publication bias or heterogeneity. Conclusion: Circulating levels of IGF-1, IGFBP-3 and their molar ratio were not associated with the risk of occurrence of CRA, but IGF-1 was associated with the increased risk for occurrence of advanced CRA.
AB - Backgrounds: Insulin-like growth factor-1(IGF-1) promotes cell proliferation and inhibits apoptosis, and is thereby implicated in carcinogenesis. Insulin-like growth factor binding protein-3 (IGFBP-3) may antagonize IGF-1 action, leading to inhibition of the potential tumorigenicity of IGF-1. We conducted this meta-analysis to estimate the association between IGF-1, IGFBP-3 and IGF-1/IGFBP-3 ratio and the risk of colorectal adenomas (CRAs). Further, we investigated whether this association was different between occurrent and recurrent CRA, by adjustment for obesity, and by advanced CRA. Materials and methods: Pubmed and Embase were searched up to April, 2015 to identify relevant observational studies and summary odds ratio (OR) and the corresponding 95% confidence interval (95% CI) was estimated using a random-effects model. Results: A total of 12 studies (11 studies including 3038 cases for IGF-1, 12 studies including 3208 cases for IGFBP-3, and 7 studies including 1867 cases for IGF-1/IGFBP-3 ratio) were included in this meta-analysis. The summary ORs of occurrent CRA for the highest versus lowest category of IGF-1, IGFBP-3 and IGF-1/IGFBP-3 ratio were 1.13 (95% CI: 0.95-1.34), 0.99 (0.84-1.16), and 1.05 (0.86-1.29), respectively. Higher IGF-1 and IGF-1/IGFBP-3 ratio were significantly associated with decreased risk of recurrent CRA (OR for IGF-1 = 0.60 [95% CI: 0.42-0.85]; IGF-1/IGFBP-3 ratio = 0.65 [0.44-0.96]). A stratified analysis by advancement of occurrent CRA produced a significant summary OR of IGF-1 for advanced CRA (OR = 2.21 [1.08-4.52]) but not for non-advanced CRA (OR = 0.89 [0.55-1.45]). We did not find significant publication bias or heterogeneity. Conclusion: Circulating levels of IGF-1, IGFBP-3 and their molar ratio were not associated with the risk of occurrence of CRA, but IGF-1 was associated with the increased risk for occurrence of advanced CRA.
KW - Advanced adenoma
KW - Colorectal adenoma
KW - Insulin-like growth factor binding protein-3
KW - Insulin-like growth factor-1
KW - Meta-analysis
KW - Neoplasm recurrence
UR - http://www.scopus.com/inward/record.url?scp=84951569952&partnerID=8YFLogxK
U2 - 10.1016/j.canep.2015.09.004
DO - 10.1016/j.canep.2015.09.004
M3 - Article
C2 - 26388613
AN - SCOPUS:84951569952
SN - 1877-7821
VL - 39
SP - 1026
EP - 1035
JO - Cancer Epidemiology
JF - Cancer Epidemiology
IS - 6
ER -
